No clinically significant changes in the pharmacokinetics of POTELIGEO were observed based on age, renal impairment, or mild/moderate hepatic impairment. As a result, no corresponding dose modifications are required.
In MAVORIC, 51% of patients treated with POTELIGEO were 65 years of age or older (range: 25 to 101)
No overall differences in effectiveness were observed between patients 65 or older and younger patients
Patients 65 or older had a greater number of grade 3 or higher adverse reactions than patients under 65, but the difference was not statistically significant